Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML).

Philipp M, Schwaab J, Dietz CT, Hanfstein B, Kalmanti L, Munjal U, Mossner M, Nowak D, Seifarth W, Hofmann WK, Hochhaus A, Müller MC, Erben P.

J Cancer Res Clin Oncol. 2014 Mar;140(3):411-7. doi: 10.1007/s00432-013-1579-x. Epub 2014 Jan 5.

PMID:
24390277
2.

ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.

Ferreira AF, Moura LG, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, Calin GA, Ivan C, Covas DT, Kashima S, Castro FA.

Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):47-55. doi: 10.1016/j.bcmd.2014.02.008. Epub 2014 Mar 11. Erratum in: Blood Cells Mol Dis. 2015 Dec;55(4):420.

PMID:
24629639
3.

Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.

Ye YX, Zhou J, Zhou YH, Zhou Y, Song XB, Wang J, Lin L, Ying BW, Lu XJ.

Asian Pac J Cancer Prev. 2014;15(22):9961-6.

4.

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.

Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A.

J Clin Oncol. 2009 Sep 1;27(25):4204-10. doi: 10.1200/JCO.2009.21.8230. Epub 2009 Aug 3.

5.

Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.

Gleixner KV, Ferenc V, Peter B, Gruze A, Meyer RA, Hadzijusufovic E, Cerny-Reiterer S, Mayerhofer M, Pickl WF, Sillaber C, Valent P.

Cancer Res. 2010 Feb 15;70(4):1513-23. doi: 10.1158/0008-5472.CAN-09-2181. Epub 2010 Feb 9.

6.

Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.

Lewandowski K, Warzocha K, Hellmann A, Skotnicki A, Prejzner W, Foryciarz K, Sacha T, Gniot M, Majewski M, Solarska I, Nowak G, Wasag B, Kobelski M, Scibiorski C, Siemiatkowski M, Lewandowska M, Komarnicki M.

Pol Arch Med Wewn. 2009 Dec;119(12):789-94.

7.

hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia.

Campbell LJ, Fidler C, Eagleton H, Peniket A, Kusec R, Gal S, Littlewood TJ, Wainscoat JS, Boultwood J.

Leukemia. 2006 Apr;20(4):671-9.

PMID:
16498395
8.

Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.

Thota NK, Gundeti S, Linga VG, Coca P, Tara RP; Raghunadharao.

Indian J Cancer. 2014 Jan-Mar;51(1):5-9. doi: 10.4103/0019-509X.134598.

9.

Status of leptin in MBCR-ABL p210 positive chronic myeloid leukemia patients before and after imatinib therapy: a conflicting scenario.

Bansal P, Ghalaut VS, Sharma TK, Ghalaut PS, Dokwal S, Ghalaut R, Kulshrestha M, Dahiya K.

Clin Lab. 2014;60(11):1845-52.

PMID:
25648025
10.

Expression of multidrug resistance 1 gene in association with CXCL12 in chronic myelogenous leukaemia.

Onishi I, Nakagawa Y, Murayama T, Hidaka M, Yamamoto K, Abe-Suzuki S, Abe S, Kurata M, Kitagawa M.

Pathology. 2014 Dec;46(7):623-9. doi: 10.1097/PAT.0000000000000180.

PMID:
25393253
11.

Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.

Kim SH, Kim D, Kim DW, Goh HG, Jang SE, Lee J, Kim WS, Kweon IY, Park SH.

Hematol Oncol. 2009 Dec;27(4):190-7. doi: 10.1002/hon.894.

PMID:
19274615
12.

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.

Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP.

Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17. Erratum in: Lancet Oncol. 2011 Oct;12(11):989.

PMID:
21856226
13.

AHI1 gene expression levels and BCR-ABL1 T315I mutations in chronic myeloid leukemia patients.

Balci TB, Sahin FI, Karakus S, Ozdogu H.

Hematology. 2011 Nov;16(6):357-60. doi: 10.1179/102453311X13127324303272.

PMID:
22183070
14.

FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.

Crescenzi B, Chase A, Starza RL, Beacci D, Rosti V, Gallì A, Specchia G, Martelli MF, Vandenberghe P, Cools J, Jones AV, Cross NC, Marynen P, Mecucci C.

Leukemia. 2007 Mar;21(3):397-402. Epub 2007 Jan 11.

PMID:
17215855
15.

Targeted chronic myeloid leukemia therapy: seeking a cure.

Fausel C.

J Manag Care Pharm. 2007 Oct;13(8 Suppl A):8-12. Review.

16.
17.

[Research advance on molecular genetics of CML blast crisis].

Zhu HQ, Zhang S, Liu XL.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Feb;16(1):217-21. Review. Chinese.

PMID:
18315935
18.

Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.

Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM, Andreeff M, Carter BZ.

Mol Cancer Ther. 2009 Sep;8(9):2509-16. doi: 10.1158/1535-7163.MCT-09-0386. Epub 2009 Sep 1.

19.

Correlation of C/EBPα expression with response and resistance to imatinib in chronic myeloid leukaemia.

Kagita S, Uppalapati S, Gundeti S, Digumarti R.

Jpn J Clin Oncol. 2015 Aug;45(8):749-54. doi: 10.1093/jjco/hyv064. Epub 2015 Apr 28.

PMID:
25920395
20.

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.

Carter BZ, Mak PY, Mak DH, Ruvolo VR, Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE, Konopleva M, Andreeff M.

Oncotarget. 2015 Oct 13;6(31):30487-99. doi: 10.18632/oncotarget.5890.

Supplemental Content

Support Center